Clinical Trial: Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma

U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07614035) titled 'Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma' on May 18.

Brief Summary: Bispecific antibodies have demonstrated high efficacy in the treatment of Refractory/relapsed b-cell non-Hodgkin lymphomas. However, a non-negligible percentage of patients do not respond to therapy and/or develop significant treatment toxicity.

Study Start Date: June 30

Study Type: OBSERVATIONAL

Condition: Non-Hodgkin Lymphoma

Recruitment Status: NOT_YET_RECRUITING

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Disclaimer: Curated by HT Syndication....